Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study

Marie Stiborova1, Zuzana Manhartova2, Petr Hodek3

  • 1Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128-40 Prague 2, Czech Republic. stiborov@natur.cuni.cz.

Insights

Encapsulating anticancer drug ellipticine in nanoparticles (PAGE-PEO) effectively forms DNA adducts in vivo, similar to free ellipticine. This micellar delivery system shows promise for cancer treatment, potentially leveraging the enhanced permeation and retention effect.

Area of Science:

  • Nanomedicine
  • Pharmacology
  • Biochemistry

Background:

  • Effective cancer treatment requires efficient drug delivery and imaging methods.
  • Nanomaterials offer unique properties for targeted drug delivery.
  • Ellipticine is an anticancer compound that forms DNA adducts.

Purpose of the Study:

  • To investigate if micelle-encapsulated ellipticine releases to form DNA adducts in vivo.
  • To compare the efficacy of micellar ellipticine versus free ellipticine in forming DNA adducts.
  • To explore the potential of nanoparticle-based ellipticine delivery for cancer therapy.

Main Methods:

  • Utilized the (32)P-postlabeling technique for detecting and quantifying DNA adducts.
  • Administered free ellipticine and micellar ellipticine (PAGE-PEO nanoparticles) to rats in vivo.
  • Compared the formation of ellipticine-DNA adducts between the two delivery methods.

Main Results:

  • Micellar ellipticine successfully formed ellipticine-derived DNA adducts in rats.
  • The formation of DNA adducts by micellar ellipticine was comparable to free ellipticine.
  • Demonstrated the in vivo efficacy of nanoparticle-encapsulated ellipticine.

Conclusions:

  • Ellipticine released from micelles can form DNA adducts, similar to free ellipticine.
  • The PAGE-PEO micellar system is a viable delivery method for ellipticine.
  • Gradual release from micelles may enhance drug delivery via the EPR effect.